Go to the list of all blogs
M. Benett's Avatar
published in Blogs
Nov 16, 2026
TickeronGET DAILY SIGNALS
Why Is Co-Diagnostics, Inc. (CODX) Stock Down -9.84% Today?

Why Is Co-Diagnostics, Inc. (CODX) Stock Down -9.84% Today?

Key Takeaways

  • Co-Diagnostics shares fell 9.84% to $0.2332 shortly after 10:40 a.m. ET Monday, compared with Friday's closing price of $0.2586.
  • No new press release, SEC filing, analyst action or corporate announcement explained Monday's leg lower.
  • Liquidity remains the dominant driver: cash totaled $714,803 at Sept. 30 against a $6.3 million quarterly net loss and $20.7 million of nine-month operating cash burn.
  • A dilution and reverse-split overhang grew heavier after shareholders approved expanded share authorities on Nov. 13.
  • Broader market and biotech benchmarks also traded lower Monday, adding pressure to a micro-cap with a thin order book.
  • News Significance Score: 28/100 — moderate verified corporate news combined with a decline only about twice the stock's normal daily swing.
  • Traders are now watching India's CDSCO decision on the CoSara TB test, the FDA review of the Flu A/B & RSV submission, and any new financing.
  • Investors can review Price Targets, Earnings and Forecast data for CODX on Tickeron's dedicated pages for deeper fundamental and technical research.
  • Readers can also explore Trending AI Robots to see which automated strategies are performing best in the current market environment.

CODX Extends Post-Earnings Slide to a Fresh 52-Week Low

Co-Diagnostics, Inc. (CODX) is a Salt Lake City-based molecular diagnostics company that develops PCR reagents and its Co-Dx PCR testing platform for point-of-care and at-home use, along with vector-control and agricultural tests. Its shares were down 9.84% at $0.2332 in Monday's session, against a prior close of $0.2586. The stock opened at $0.25, touched $0.225 — a new 52-week low — and remained deep in negative territory. No verified news catalyst was published for Monday's decline; the move extends a repricing that followed the company's third-quarter report on Nov. 10 and its Nov. 13 special shareholder meeting.

Liquidity Fears Dominate After Q3 Results

The core of the bear case is cash. Third-quarter revenue rose to $282,881 from $145,380 a year earlier, and operating expenses fell 12% to $6.25 million, but the company still posted a net loss of $6.31 million, or $1.01 per share. Cash and equivalents stood at just $714,803 on Sept. 30 after $20.7 million of operating cash use in the first nine months of 2026. Management disclosed a subsequent senior secured convertible note financing of roughly $2.1 million, with $1.0 million more available subject to conditions — a sum that buys months, not years, of runway at the current burn rate. None of this was new on Monday, but with no product approved for sale on the Co-Dx PCR platform, the market has continued to discount the equity accordingly.

Reverse-Split Authorization Adds a Dilution Overhang

At the Nov. 13 special meeting, shareholders approved a set of proposals that increases the share count available for future issuance, including warrants for 3.4 million shares and shares underlying the convertible notes, plus a reverse stock split at ratios of no less than 1-for-2 with a cumulative effect capped at 1-for-750. Reverse-split authority typically becomes relevant when a stock trades well below Nasdaq's $1.00 minimum bid, and CODX has traded under that threshold since September. For holders, the combination of authorized share expansion and split authority signals more potential dilution ahead rather than a resolution of the funding gap.

Regulatory Progress Has Not Offset the Cash Problem

Operationally, the company has two submissions under review: a dual 510(k) and CLIA Waiver by Application for its Flu A/B & RSV test filed with the FDA in August, and the CoSara PCR MTB tuberculosis test submitted to India's CDSCO, which showed roughly 97.3% sensitivity and 96% specificity in clinical study. Both are potentially meaningful for a company with a market value of about $2.5 million, but neither generates revenue today, and management offered no guidance on the Nov. 10 call, which consisted of prepared remarks only with no question-and-answer session.

Market Context and Trading Activity

Turnover was not heavy: roughly 80,000 shares changed hands in the first 45 minutes, about a quarter of the stock's recent full-day average near 340,000 shares, suggesting thin liquidity rather than a single large seller. The decline came alongside broad weakness, with the S&P 500-tracking SPDR fund down about 1.1% and major biotech exchange-traded funds off 0.7% to 1.3%, though CODX's move was far larger than any sector benchmark. Technically, the stock lost the $0.2450 low from Nov. 13 and trades roughly 70% below its 50-day moving average near $0.80 and about 89% below its 200-day average near $2.07, with momentum deeply oversold.

News Significance Score

On a scale where 0 means no meaningful news and a move entirely normal for the stock, and 100 means transformative news and an extreme, rare price move, Co-Diagnostics scores 28 out of 100. The verified news is material for a company this small — a $6.3 million quarterly loss, $714,803 of cash, a new convertible note and freshly approved share and reverse-split authorities — but it was disclosed between Nov. 10 and Nov. 13 and is largely reflected in the price already.

The decline itself was about 1.9 times the stock's typical daily move of roughly 5.1%, and moves of this magnitude have occurred 10 times in the past 69 sessions. Moderate news and a modest anomaly combine into a low-to-mid score.

What Comes Next for CODX

The next scheduled financial update is not expected until roughly late March 2027, leaving investors to trade headlines in the interim. Near-term catalysts include a CDSCO decision on the TB test, which the company has indicated could precede a commercial launch in India before the end of 2026, and continued FDA review of the respiratory panel. Management's presence at global tuberculosis events in Rio de Janeiro this week may generate updates. The principal risks are a dilutive equity raise, continued cash burn, potential Nasdaq listing pressure and the possibility that either regulatory submission is delayed or rejected. Analysts remain sparsely covering the name, and expectations should be treated cautiously given the absence of formal guidance.

Trending AI Robots

Tickeron offers hundreds of AI trading bots spanning thousands of tickers, but only the strongest performers under current market conditions appear in its curated Trending AI Robots section. Each bot differs by strategy, timeframe, performance metrics and the symbols it trades, so the lineup rotates as market conditions change. For traders navigating volatile micro-caps like this one, reviewing the current leaders can help frame risk and timing decisions. Explore the page to see which automated strategies are working right now.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: CODX

CODX in upward trend: price may jump up because it broke its lower Bollinger Band on October 14, 2026

CODX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 29 of 34 cases where CODX's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 85%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Indicator shows that the ticker has stayed in the oversold zone for 22 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 22 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

The Moving Average Convergence Divergence (MACD) for CODX just turned positive on November 11, 2026. Looking at past instances where CODX's MACD turned positive, the stock continued to rise in 32 of 40 cases over the following month. The odds of a continued upward trend are 80%.

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on October 13, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on CODX as a result. In 75 of 85 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 88%.

CODX moved below its 50-day moving average on October 13, 2026 date and that indicates a change from an upward trend to a downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where CODX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.

The Aroon Indicator for CODX entered a downward trend on November 13, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 6 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of 45 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.141) is normal, around the industry mean (4.142). P/E Ratio (-0.010) is within average values for comparable stocks, (3.291). Projected Growth (PEG Ratio) (0.010) is also within normal values, averaging (11.253). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (3.171) is also within normal values, averaging (40.124).

The Tickeron Price Growth Rating for this company is 97 (best 1 - 100 worst), indicating slightly worse than average price growth. CODX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CODX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

Notable companies

The most notable companies in this group are Abbott Laboratories (NYSE:ABT), Medtronic plc (NYSE:MDT), Boston Scientific Corp (NYSE:BSX), Edwards Lifesciences Corp (NYSE:EW).

Industry description

The medical/nursing services includes companies that provide medical-related services such as ambulance services, dialysis centers, respiratory therapy, blood testing and rehabilitation services. DaVita Inc., Chemed Corporation and Guardant Health, Inc. are examples of companies in this industry.

Market Cap

The average market capitalization across the Medical/Nursing Services Industry is 6.17B. The market cap for tickers in the group ranges from 837 to 190.22B. ABT holds the highest valuation in this group at 190.22B. The lowest valued company is DHAI at 837.

High and low price notable news

The average weekly price growth across all stocks in the Medical/Nursing Services Industry was 1%. For the same Industry, the average monthly price growth was -4%, and the average quarterly price growth was -6%. POAS experienced the highest price growth at 351%, while NPCE experienced the biggest fall at -40%.

Volume

The average weekly volume growth across all stocks in the Medical/Nursing Services Industry was 28%. For the same stocks of the Industry, the average monthly volume growth was 24% and the average quarterly volume growth was 13%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 48
P/E Growth Rating: 49
Price Growth Rating: 60
SMR Rating: 89
Profit Risk Rating: 94
Seasonality Score: 13 (-100 ... +100)
1-on-1 3
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a developer of molecular diagnostics products and tests that represents a radical new advancement in the understanding of the molecular interactions of DNA

Industry MedicalNursingServices

Industry
Biotechnology
Address
2401 S. Foothill Drive
Phone
+1 801 438-1036
Employees
115
Web
https://www.codiagnostics.com
Interact to see
Advertisement
NVIDIA shares declined roughly 26% over the 30 days ending mid-November, falling from a close near $221 to $162.85. The drop left the stock about 30% below its October 6 record intraday high of $243.37 and at a 52-week low.
Micron shares fell -6.28% to $729.40 from Friday's $778.31 close, gapping lower in premarket trading and holding those losses into Monday's regular session. The decline was sector-driven, not company-specific: memory peers SanDisk, SK hynix and Western Digital slid in tandem as last week's Nvidia CEO departure revived doubts over AI data-center spending, financing and memory demand durability.
ACHR fell -7.44% in Monday's regular session, sliding from Friday's $4.03 close to $3.73 shortly after 10 a.m. ET — a third consecutive daily decline that pushed shares back toward their November 5 low. No verified news or fundamental catalyst found for today's leg lower; the selling extends the de-rating that followed Q3 results — revenue of just $5.1 million, a net loss widening 111% to $274.6 million, and price-target cuts from Cantor Fitzgerald, Needham and Canaccord.
Dell Technologies (DELL) fell roughly 23.7% over the last 30 days, sliding from a closing price of $451.71 on October 16, 2026, to $344.53 on November 13, 2026. The decline accelerated after the U.S. midterm elections, when investor concerns about potential AI and data-center regulation triggered a sharp sell-off across AI hardware names.
SKHY fell -6.87% to $122.74 by 10:04 a.m. ET, down $9.05 from Friday's close of $131.79, extending a premarket decline into the regular session. The drop was driven by a sector-wide AI chip selloff ahead of Nvidia's quarterly results on Tuesday, where CEO Jensen Huang's resignation has raised doubts about the durability of data-center spending that underpins high-bandwidth memory demand.